Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Metastatic melanoma has a poor prognosis due to resistance to multiple chemotherapy regimens. The mainstay of treatment remains dacarbazine, with cisplatin being a commonly used alternative. Melanoma displays marked resistance to the DNA-damaging effects of these drugs. Intrinsic and acquired resistance involves multiple cellular pathways of damage recognition, repair and apoptosis. Increased understanding of these pathways is identifying novel targets that it is hoped will make inroads into the treatment of this lethal disease.

Type

Journal article

Journal

Anticancer Drugs

Publication Date

06/2004

Volume

15

Pages

421 - 426

Keywords

Antineoplastic Agents, Apoptosis, DNA Repair, Drug Resistance, Neoplasm, Humans, Melanoma, Neoplasm Metastasis, O(6)-Methylguanine-DNA Methyltransferase